|
Home:
Educational
Supplement: Section 10
SELECT PUBLICATIONS
Ali SM et al.
Safety and efficacy of bisphosphonates beyond 24 months in cancer
patients. J Clin Oncol 2001;19(14):3434-3437. Abstract
Anonymous.
British Association of Surgical Oncology Guidelines. The management
of metastatic bone disease in the United Kingdom. The Breast Specialty
Group of the British Association of Surgical Oncology. Eur
J Surg Oncol 1999;25:3-23. Abstract
Berenson JR,
Lipton A. Pharmacology and clinical efficacy of bisphosphonates
. Current Opinion in Oncology 1998;10:566-71. Abstract
Berenson JR,
Lipton A. Use of bisphosphonates in patients with metastatic
bone disease. Oncology (Huntington) 1998;12:1573-9;
discussion 1579-81. Abstract
Berenson JR,
Lipton A. Bisphosphonates in the treatment of malignant bone
disease. Ann Review Med 1999;50:237-48. Abstract
Bloomfield
DJ. Should bisphosphonates be part of the standard therapy of
patients with multiple myeloma or bone metastases from other cancers?
An evidence-based review. J Clin Oncol 1998;16:1218-
25. Abstract
Body JJ et
al. Current use of bisphosphonates in oncology. International
Bone and Cancer Study Group. J Clin Oncol 1998;16:3890-9.
Abstract
Body JJ. Bisphosphonates.
Eur J Cancer 1998;34:263-9. Abstract
Body JJ. Clinical
research update: zoledronate. Cancer 1997;80:1699- 701.
Abstract
Body JJ et
al. Use of bisphosphonates in cancer patients. Cancer
Treatment Reviews 1996;22:265-87. Abstract
Body JJ. Clinical
trials in metastatic breast cancer to bone: past— present—future.
Canadian Journal of Oncology 1995;5 Suppl 1:16-27. Abstract
Coleman RE.
How can we improve the treatment of bone metastases further?
Current Opinion in Oncology 1998;10 Suppl 1:S7-13. Abstract
Coleman RE.
Skeletal complications of malignancy. Cancer 1997;80:1588-94.
Abstract
Coleman RE
et al. The future of bisphosphonates in cancer. Acta Oncologica
1996;35 Suppl 5:23-9. Abstract
Crandall C.
Risedronate: A clinical review. Arch Intern Med 2001;161(3):353-60.
Abstract
Crawshaw A.
Carcinoma of the breast and hormone replacement therapy for osteoporosis.
International Journal of Clinical Practice 2000;54:99-103.
Abstract
Cristofanilli
M & Hortobagyi GN. Bisphosphonates in the management of breast
cancer. Cancer Control 1999;6(3):241-246. Full-Text
Crohns CA, Untch
M. Different bisphosphonates have direct cytotoxic effects on
three breast cancer cell lines and fresh breast cancer tumor tissue.
Proc ASCO 2001;Abstract
2005.
Cutson TM, Meuleman
E. Managing menopause. American Family Physician 2000;61:1391-400.
Abstract
Diel IJ. Antitumour
effects of bisphosphonates: First evidence and possible mechanisms.
Drugs 2000;59:391-9. Abstract
Diel
IJ, Mundy GR. Bisphosphonates in the adjuvant treatment of cancer:
experimental evidence and first clinical results. International
Bone and Cancer Study Group (IBCG). British Journal of Cancer
2000;82:1381-6. Abstract
Diel IJ et
al. Bisphosphonates and the prevention of metastasis: First evidences
from preclinical and clinical studies. Cancer 2000;88:3080-
8. Abstract
Diel IJ et
al. Reduction in new metastases in breast cancer with adjuvant
clodronate treatment. N Engl J Med 1998;339:357-63. Abstract
Hillner BE
et al. For the American Society of Clinical Oncology Bisphosphonates
Expert Panel. American Society of Clinical Oncolog y Guideline on
the Role of Bisphosphonates in Breast Cancer. Full-Text
Harvey HA. Issues
concerning the role of chemotherapy and hormonal therapy of bone
metastases from breast carcinoma. Cancer 1997;80:1646-51.
Abstract
Houston SJ,
Rubens RD. The systemic treatment of bone metastases. Clinical
Orthopaedics & Related Research 1995:95-104. Abstract
Hurst M, Noble
S. Clodronate: A review of its use in breast cancer. Drugs
& Aging 1999;15:143-67. Abstract
Kanis JA. Rationale
for the use of bisphosphonates in breast cancer. Acta Oncologica
1996;35 Suppl 5:61-7. Abstract
Kennedy MJ.
Metastatic breast cancer. Current Opinion in Oncology
1996;8:485-90. Abstract
Klijn JG et
al. Novel endocrine therapies in breast cancer. Acta Oncologica
1996;35 Suppl 5:30-7. Abstract
Kennedy MJ.
Systemic therapy for breast cancer. Current Opinion in
Oncology 1997;9:532-9. Abstract
Lipton A. Bisphosphonates
and breast carcinoma. Cancer 1997;80:1668-73. Abstract
Lipton A. Aredia:
The once-monthly infusion for the treatment of bone metastases.
Current Opinion in Oncology 1998;10 Suppl 1:S1-5. Abstract
Major PP et
al. Oral bisphosphonates: A review of clinical use in patients
with bone metastases. Cancer 2000;88:6-14. Abstract
Merlini G,
Turesson I. Utility of bisphosphonates in treating bone metastases.
Medical Oncology 1996;13:215-21. Abstract
Moore HC. Managing
menopause after breast cancer: Balancing risks and benefits.
Cleve Clin J Med 2001;68(3):243-8. Abstract
Mundy GR. Mechanisms
of bone metastasis. Cancer 1997;80:1546-56. Abstract
Nikolic-Tomasevic
Z et al. Tumor ‘flare’ hypercalcemia—an additional
indication for bisphosphonates? Oncology 2001;60(2):123-
6. Abstract
Paterson AH.
The potential role of bisphosphonates as adjuvant therapy in
the prevention of bone metastases. Cancer 2000;88:3038-
46. Abstract
Perez EA. Management
of bone metastases in advanced breast cancer. Cancer Control
1999;6(5,Suppl). Full-Text
Powles TJ et
al. Adjuvant clodronate reduces the incidence of bone metastases
in patients with primary operable breast cancer. Proc ASCO
1998; Abstract
468
Pritchard KI.
Endocrine therapy for breast cancer. Oncology (Huntington)
2000;14:483-92; discussion 493. Abstract
Saarto T et
al. Adjuvant clodronate treatment does not reduce the frequency
of skeletal metastases in node-positive breast cancer patients:
5-year results of a randomized controlled trial. J Clin Oncol
2001;19:10-17. Abstract
Top
Additional
Sections:
1 | 2
| 3 | 4
| 5 | 6
| 7 | 8
| 9 | 10
| 11 | 12
|
|
